Last reviewed · How we verify
AZD0171
AZD0171 is a small molecule inhibitor of the PI3K delta subunit.
AZD0171 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Relapsed or refractory follicular lymphoma.
At a glance
| Generic name | AZD0171 |
|---|---|
| Also known as | MSC-1 |
| Sponsor | AstraZeneca |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K delta subunit, AZD0171 is thought to modulate the immune response and potentially treat various diseases.
Approved indications
- Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Relapsed or refractory follicular lymphoma
Common side effects
- Pneumonia
- Diarrhea
- Nausea
- Fatigue
- Cough
Key clinical trials
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (PHASE2)
- Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD0171 CI brief — competitive landscape report
- AZD0171 updates RSS · CI watch RSS
- AstraZeneca portfolio CI